Literature DB >> 21212370

Dynamic contrast-enhanced MR imaging measurement of vertebral bone marrow perfusion may be indicator of outcome of acute myeloid leukemia patients in remission.

Bang-Bin Chen1, Chao-Yu Hsu, Chih-Wei Yu, Hsin-An Hou, Chieh-Yu Liu, Shwu-Yuan Wei, Wen-Chien Chou, Hwei-Fang Tien, Tiffany Ting-Fang Shih.   

Abstract

PURPOSE: To examine whether dynamic contrast material-enhanced (DCE) magnetic resonance (MR) imaging measurement of bone marrow perfusion in acute myeloid leukemia (AML) patients in complete remission (CR) is associated with outcome and survival.
MATERIALS AND METHODS: After institutional review board approval and informed consent were obtained, from September 2004 to October 2007, 51 patients (29 women, 22 men; mean age, 43.5 years; range, 17-66 years) agreed to undergo DCE MR imaging to assess bone marrow perfusion, among 96 patients with newly diagnosed de novo AML who had received induction chemotherapy and achieved CR. Two semiquantitative parameters (peak and slope) and another three quantitative parameters (amplitude, K(ep) [efflux rate constant], and K(el) [elimination rate constant]) were calculated. Overall survival (OS) and relapse-free survival (RFS) were assessed with the Kaplan-Meier model, while differences between patient groups with high and low DCE MR imaging parameter values were assessed by using the two-sided log-rank test.
RESULTS: The median follow-up was 25.9 months. Univariate analysis results showed that high values of peak (≥0.42), slope (≥0.0235), amplitude (≥0.03), and K(ep) (≥0.0082) were associated with shorter OS (P = .004, 0.01, 0.034, and 0.026, respectively). Besides, a high value of K(ep) was also associated with shorter RFS (P = .008). When age, sex, and initial karyotype at diagnosis were included in multivariate Cox proportional hazards analysis, the results showed that only K(ep), but not other DCE MR imaging parameters, was an independent factor for OS (relative risk [RR], 30.305; P = .021) and RFS (RR, 6.477; P = .009).
CONCLUSION: Bone marrow perfusion measured with DCE MR imaging in AML patients in CR can be an indicator of outcome and survival. K(ep) measured with kinetic modeling was useful and significantly associated with RFS, while heuristic parameters (peak and slope) were not. © RSNA, 2011.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21212370     DOI: 10.1148/radiol.10100995

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  10 in total

1.  Time dependency of bone density estimation from computed tomography with intravenous contrast agent administration.

Authors:  K Acu; M Scheel; A S Issever
Journal:  Osteoporos Int       Date:  2013-07-23       Impact factor: 4.507

2.  Functional imaging of the musculoskeletal system.

Authors:  James F Griffith
Journal:  Quant Imaging Med Surg       Date:  2015-06

3.  Dynamic contrast-enhanced MR imaging in osteoid osteoma: relationships with clinical and CT characteristics.

Authors:  P Pottecher; E Sibileau; S Aho; B Hamze; C Parlier; J D Laredo; V Bousson
Journal:  Skeletal Radiol       Date:  2017-04-11       Impact factor: 2.199

4.  Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer.

Authors:  Bang-Bin Chen; Yen-Shen Lu; Chih-Wei Yu; Ching-Hung Lin; Tom Wei-Wu Chen; Shwu-Yuan Wei; Ann-Lii Cheng; Tiffany Ting-Fang Shih
Journal:  Eur Radiol       Date:  2018-05-16       Impact factor: 5.315

5.  Diagnosis of Spinal Lesions Using Heuristic and Pharmacokinetic Parameters Measured by Dynamic Contrast-Enhanced MRI.

Authors:  Ning Lang; Huishu Yuan; Hon J Yu; Min-Ying Su
Journal:  Acad Radiol       Date:  2017-02-02       Impact factor: 3.173

Review 6.  Bone marrow MR perfusion imaging and potential for tumor evaluation.

Authors:  James F Griffith; R A van der Heijden
Journal:  Skeletal Radiol       Date:  2022-10-22       Impact factor: 2.128

7.  Angiogenesis in acute myeloid leukemia and opportunities for novel therapies.

Authors:  Angelica Trujillo; Christie McGee; Christopher R Cogle
Journal:  J Oncol       Date:  2011-09-05       Impact factor: 4.375

8.  A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.

Authors:  Bang-Bin Chen; Yen-Shen Lu; Ching-Hung Lin; Wei-Wu Chen; Pei-Fang Wu; Chao-Yu Hsu; Chih-Wei Yu; Shwu-Yuan Wei; Ann-Lii Cheng; Tiffany Ting-Fang Shih
Journal:  BMC Cancer       Date:  2016-07-13       Impact factor: 4.430

9.  Early assessment of response to induction therapy in acute myeloid leukemia using 18F-FLT PET/CT.

Authors:  Eun Ji Han; Bo-Hee Lee; Jeong-A Kim; Young Ha Park; Woo Hee Choi
Journal:  EJNMMI Res       Date:  2017-09-16       Impact factor: 3.138

10.  Evaluation of Early Response to Treatment of Hepatocellular Carcinoma with Yttrium-90 Radioembolization Using Quantitative Computed Tomography Analysis.

Authors:  Sungwon Kim; Do Young Kim; Chansik An; Kyunghwa Han; Jong Yun Won; Gyoung Min Kim; Myeong Jin Kim; Jin Young Choi
Journal:  Korean J Radiol       Date:  2019-03       Impact factor: 3.500

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.